HLB Group to Deliver 'Plenary Oral Presentation' at AACR 2026... Unveils Four Research Achievements
HLB Group announced that it will present four research achievements at the American Association for Cancer Research (AACR 2026), the world’s largest academic conference for cancer research, which will be held in San Diego, United States, starting April 17 (local time).
According to the official AACR program, three abstracts by Verrismo Therapeutics, a subsidiary of HLB Innovation, and one abstract by Elevar Therapeutics, a subsidiary of HLB, have been listed.
Interim results from the Phase 1 (STAR-101) clinical trial of Verrismo’s chimeric antigen receptor T-cell (CAR-T) therapy ‘SynKIR-110’ for solid tumors have been selected for an oral presentation. Notably, this study has been included in the plenary session, where only research with significant meaning and impact is carefully chosen, thereby demonstrating both the clinical value of the study and its high visibility at this global academic event.
Preclinical results for the CAR-T therapy ‘SynKIR-310’ targeting hematologic cancers have also been selected for a poster presentation. The study will present data showing that SynKIR-310 demonstrated superior antitumor efficacy compared to conventional CD3-based CAR-T cells in a B-cell non-Hodgkin lymphoma xenograft mouse model, and that the initial clinical signals support the potential for future clinical development.
Preclinical data on an EGFR-targeted KIR-CAR for glioblastoma, produced in collaboration with researchers from the University of Pennsylvania, will also be presented as a poster. This study contains preclinical results showing meaningful antitumor effects in resistant glioblastoma models, overcoming the limitations of existing CAR-T therapies. The differentiated and expandable nature of Verrismo’s proprietary ‘KIR-CAR’ platform technology has drawn particular attention. Elevar Therapeutics will also release a poster presentation comparing the high selectivity of its FGFR2-targeted anticancer drug ‘Lirafugratinib’ with existing pan-FGFR inhibitors.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An HLB Group representative stated, “This AACR 2026 presentation is an important milestone demonstrating that the competitiveness of our major pipelines, including SynKIR-based cell therapies and FGFR2-targeted anticancer drugs, is being substantiated through clinical and preclinical data.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.